Heart failure & cardiomyopathies
Prevalence and Clinical Implications of Sleep Apnea in Hypertrophic Cardiomyopathy
An erratum to this article was published (JAMA Cardiol, 1 Apr 2026 ↗)
Authors' conclusion
This study suggests that undiagnosed SDB is highly prevalent in patients with HCM and that SDB is associated with adverse myocardial remodeling, greater diastolic dysfunction, and elevated troponin-T levels, indicating subclinical myocardial injury.
Study context
- Population
- Adults with hypertrophic cardiomyopathy (HCM) (LV wall thickness ≥15 mm or pathogenic variants) without known sleep disordered breathing (SDB), single tertiary referral centre, 2018–2024
- Participants
- 154 adults
- Exposure
- SDB vs no SDB
- SDBn = 91
- Outcome
- Prevalence of SDB; echocardiographic indices, cardiac biomarkers, functional status, apnea-hypopnea index, overnight hypoxemia
Methodological detailssingle-centre, blinded observers, Observers blinded to polysomnographic results
- Single-centre
- Blinded observers
- Observers blinded to polysomnographic results
Main finding
As reported in the abstract
Prevalence of SDB
SDB
59.1%
91
Observational data: associations, not effects.
Further findings
LV mass index
P = 0.03
Baseline troponin-T
P = 0.04
NYHA class II or III symptoms
P = 0.005
Hypertension
P = 0.03
Diabetes
P = 0.04
| Outcome | SDB | No SDB | P value |
|---|---|---|---|
| E/e' ratioMedian | 12.5 (IQR 10.0–15.0) | 10.0 (IQR 8.3–14.5) | P = 0.04 |
| Overnight troponin-T changeMedian change, ng/mL | 0.0021 (IQR −0.0029–0.0062) | 0.0002 (IQR −0.0022–0.0026) | P = 0.02 |
AF and prior myectomy
- Rates did not differ significantly between groups
Original publication
Prevalence and Clinical Implications of Sleep Apnea in Hypertrophic Cardiomyopathy. JAMA Cardiol. Published 1 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →